The Phase 2 clinical trial, sponsored by Pontificia Universidad Catolica de Chile, evaluates the immunogenicity superiority of booster doses with Omicron and trivalent vaccines compared to the CoronaVac vaccine in a previously vaccinated adult population in Chile. Given the ongoing global demand for effective COVID-19 vaccines, particularly against emerging variants, this study could position the Omicron and trivalent vaccines favorably in the competitive landscape. The results may enhance the commercial viability of these vaccines, especially if they demonstrate superior immunogenicity, potentially leading to expanded market opportunities and partnerships, particularly with Sinovac Life Sciences Co., Ltd. Furthermore, the trial's completion and subsequent data could attract interest from investors and stakeholders focused on pandemic preparedness and vaccine development.